Previous 10 | Next 10 |
IND Filed for Flagship Program ARCT-810 Coronavirus Vaccine Program Initiated Investor Conference Call at 4:30 pm ET Today SAN DIEGO, Calif., March 11, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines compa...
SAN DIEGO, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that it will provide a cor...
SAN DIEGO, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that Joseph Payne, Chief E...
Arcturus Therapeutics (NASDAQ: ARCT ) initiated with Outperform rating and $24 (96% upside) price target at Baird. More news on: Arcturus Therapeutics Holdings Inc., Curaleaf Holdings, Inc., I-Mab, Healthcare stocks news, Stocks on the move, , Read more ...
Arcturus Therapeutics (NASDAQ: ARCT ) initiated with Buy rating and $19 (70% upside) price target at Guggenheim. More news on: Arcturus Therapeutics Holdings Inc., BeyondSpring Inc., Millendo Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Investment Thesis Notwithstanding two commercialized products and a rich pipeline, the twelve-month share price decline for Ultragenyx Pharmaceutical Inc. ( RARE ) had approached ~6.5% by early 2020 compared to ~12.0% LTM (last-twelve-month) gain in the NBI (NASDAQ Biotechnology Index). ...
SAN DIEGO, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced the appointment of Steve H...
The following slide deck was published by Arcturus Therapeutics Holdings Inc. in conjunction with this Read more ...
PHILADELPHIA, PA / ACCESSWIRE / December 11, 2019 / Arcturus Therapeutics (ARCT), will be presenting at this year's Investor Summit on December 17th in Philadelphia. The Investor Summit will take place at Hotel Monaco, featuring 30 companies and over 200 institutional and retail investors....
The genetics industry supports every other life science industry, with one contribution being the discovery of new genetic drivers of diseases. In terms of the genetic testing market, this area has grown substantially over the last few years thanks to advances made in technology ; in lin...
News, Short Squeeze, Breakout and More Instantly...
Arcturus Therapeutics Ltd. Company Name:
ARCT Stock Symbol:
NASDAQ Market:
Arcturus Therapeutics Ltd. Website:
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, toda...
2024-07-02 10:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for ARCT on July 2, 2024 08:19AM ET. The previous analyst recommendation was Overweight. ARCT was trading at $23.66 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
ARCT-810 Phase 2 study completed enrollment at 0.3 mg/kg dose level in Europe with data expected later this year ARCT-810 to expand Phase 2 clinical program in the U.S. to enroll patients with more severe disease ARCT-032 IND for Phase 2 multiple ascending dose study to be submitt...